Who are Pyronaridine-artesunate (PA)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Coartem, Coartem, Qualaquin, Malarone, Halfan, Mepron.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pyronaridine-artesunate-pa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Pyronaridine-artesunate (PA) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pyronaridine-artesunate (PA) (Pyronaridine-artesunate (PA)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial. Area: Infectious Diseases.

phase 3 Antimalarial Dihydroorotate dehydrogenase, Beta-hematin formation Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Pyronaridine-artesunate (PA) (Pyronaridine-artesunate (PA)) — Liverpool School of Tropical Medicine. Pyronaridine-artesunate is a combination of pyronaridine and artesunate, which work together to inhibit the growth of malaria parasites.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pyronaridine-artesunate (PA) TARGET	Pyronaridine-artesunate (PA)	Liverpool School of Tropical Medicine	phase 3	Antimalarial	Dihydroorotate dehydrogenase, Beta-hematin formation
Coartem	LUMEFANTRINE	Novartis	marketed	Antimalarial [EPC]	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Coartem	ARTEMETHER		marketed	Antimalarial [EPC]		2009-01-01
Qualaquin	QUININE	Sun Pharm Industries	marketed	Antimalarial	Sodium channel alpha subunits; brain (Types I, II, III)	2005-01-01
Malarone	PROGUANIL	GSK	marketed	Antimalarial [EPC]		2000-01-01
Halfan	HALOFANTRINE	GSK	marketed	Antimalarial	Potassium voltage-gated channel subfamily H member 2	1992-01-01
Mepron	ATOVAQUONE		marketed	Antimalarial [EPC]	ATP-binding cassette sub-family G member 2	1992-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial class)

London School of Hygiene and Tropical Medicine · 6 drugs in this class
Sanofi · 3 drugs in this class
Epicentre · 2 drugs in this class
University of Oxford · 2 drugs in this class
· 2 drugs in this class
Frantz Viral Therapeutics, LLC · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Institut de Recherche pour le Developpement · 1 drug in this class
Centre de Recherche Médicale de Lambaréné · 1 drug in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pyronaridine-artesunate (PA) — Competitive Intelligence Brief. https://druglandscape.com/ci/pyronaridine-artesunate-pa. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab